The recent acquisition by Actavis of Warner Chilcott plc has created a leading global specialty pharmaceutical company with approximately €8 billion in anticipated, proforma, combined annual 2013 revenue, and the third-largest specialty pharmaceutical business in the US with approximately $3 billion in annual revenue.
Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women’s healthcare, gastroenterology, urology and dermatology segments of the branded pharmaceuticals market, primarily in North America. Warner Chilcott is a fully integrated company with internal resources dedicated to the development, manufacture and promotion of its products.
The combination of Actavis Pharma and Actavis Global Operations forms the foundation of Actavis plc. This combination dramatically strengthens Actavis specialty brands which develops and markets a portfolio of approximately 40 products principally in the US and Canada that are focused in the urology and women’s health therapeutic categories. It also develops and out-licenses generic pharmaceutical products outside of the US through its Medis third-party business. This combination represents a significant achievement against Actavis’ long-term strategic objective of building a leading global specialty pharmaceutical company.
The women’s health segment has now been strengthened with over 90 per cent share of voice in oral contraceptives. Additionally, the combination bolsters the urology business, and established a platform for continued expansion into the gastroenterology and dermatology therapeuticcategories.
Actavis is also pursuing a strategy to build a leadership position in biosimilars (a biotherapeutic product which is similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic product), which includes collaboration with Amgen to develop and commercialise, on a worldwide basis, biosimilar versions of Herceptin®, Avastin®, Rituxan/Mab Thera®, and Erbitux®. These products represent some of the fastest-growing pharmaceutical products in the world with peak innovator sales topping €14 billion, and we expect the collaboration to launch its first biosimilar products beginning in 2017.
Actavis plc has manufacturing sites and offices in Bulebel and Hal Far, employing approximately 900 people. The marketing and sales office in Malta is responsible for African markets and Malta, Cyprus and Israel. Globally Actavis employs approximately 17,000 people.